PT-141 CLINICAL STUDIES
PT-141 Clinical Trials: What the Studies Found
The trials behind bremelanotide's approval, and who they studied
PT-141 clinical trials were conducted under its generic name, bremelanotide, and supported its FDA approval as Vyleesi. This page looks at how those studies were designed and who they enrolled. For the legal-status question, see PT-141's regulatory status.
The Phase 3 Program
Bremelanotide was studied in two randomized, double-blind, placebo-controlled Phase 3 trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The trials measured changes in sexual desire and in the distress associated with low desire, using validated questionnaires.
Source: FDA Drug Trials Snapshots: VYLEESI.
What the Trials Measured — and Their Limits
The studies reported statistically significant improvements in desire scores and reductions in distress versus placebo, though the average effect was modest and nausea was a common side effect. Importantly, the trials studied only premenopausal women with a specific diagnosis — not men, postmenopausal women, or the general population.
Source: FDA prescribing information for VYLEESI.
Frequently Asked Questions
Who did the PT-141 trials study?
Premenopausal women with acquired, generalized HSDD.
Do the trials apply to men?
No. Men were not the studied population.
The Bottom Line
The PT-141 clinical trials are methodologically solid but specific to one group of women — which is the accurate way to summarize PT-141 clinical trials.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- FDA prescribing information for VYLEESI
- FDA Drug Trials Snapshots: VYLEESI
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →